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Abstract
Cardiac arrest with cerebral ischaemia frequently leads to severe neurological impairment. Extracorporeal life
support (ECLS) has emerged as a valuable adjunct in resuscitation of cardiac arrest. Despite ECLS, the incidence of
permanent neurological injury remains high. We hypothesize that patients receiving ECLS for cardiac arrest treated
with therapeutic hypothermia at 34 °C have lower neurological complication rates compared to standard ECLS
therapy at normothermia. Early results of this randomized study suggest that therapeutic hypothermia is safe in
adult patients receiving ECLS, with similar complication rates as ECLS without hypothermia. Further studies are
warranted to measure the efficacy of this therapy.
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Introduction
Cardiac arrest with widespread cerebral ischaemia fre-
quently leads to severe neurological impairment. Extra-
corporeal life support (ECLS) is a valuable adjunct in
resuscitation of cardiac arrest and is instituted whenever
indicated [1]. Despite ECLS, the rate of survival to
hospital discharge with good neurological function re-
mains low, ranging from 26 to 47 % [2–4].
Ischaemia has a key role in all forms of brain injury and
preventing ischaemic (or secondary) injury is at the core
of all neuroprotective strategies. Therapeutic induced
hypothermia via surface cooling has been shown to lower
the rate of neurological complications in patients resusci-
tated from cardiac arrest by up to 23 % [5, 6].
ECLS is an ideal tool for the institution of cooling as
the extracorporeal pump can achieve flow rates of up to
5 L/min. This allows for rapid and homogenous cooling
and subsequent rewarming via large bore cannulas
placed in the common femoral artery and vein. Cooling
via the ECLS circuit can be augmented with surface
cooling using cooling blankets and ice packs. To date,
there are few reports from studies evaluating the use of
therapeutic hypothermia in adult patients receiving
ECLS [2–4, 7]. The objective of this study is to evaluate
the safety and clinical efficacy of therapeutic induced
hypothermia in patients receiving ECLS following car-
diopulmonary resuscitation (CPR) for cardiac arrest.
Methods
Following approval from the SingHealth institutional
review board (reference: 2013/153/C), a randomized con-
trolled study was commenced at our tertiary referral cen-
ter, to investigate the outcome of patients who remain
unconscious after initiation of ECLS for cardiac arrest. All
patients received good quality CPR and were adequately
resuscitated by qualified medical staff prior to commence-
ment of ECLS. Patients in the control group received
ECLS at normothermia (37 °C) whereas the treatment
group received ECLS at induced hypothermia (34 °C) for
24 h. The target recruitment is 50 patients over a period
of 36 months.
Inclusion criteria
Cardiac arrest patients with ECLS instituted and any of
the following:
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 Ventricular fibrillation
 Asystole or pulseless electrical activity (PEA)
 Pulseless ventricular tachycardia
 Downtime less than 45 min. Defined as the time
from the onset of cardiac arrest to the initiation of
Advanced Cardiac Life Support (ACLS)
 Comatose patients
 Patients not responding appropriately to verbal
commands after return of spontaneous circulation
(ROSC).
 Total ACLS time <60 min
 Age ≥21 years
 Intubated with mechanical ventilation
Exclusion criteria
 Patients responding appropriately to verbal
commands after ROSC
 CPR longer than 45 min
 Severe coagulopathy with clinical evidence of
bleeding and/or platelets less than 30 × 103/mm3
and/or INR ≥2.5
 Other causes of coma (e.g. drug overdose, head
trauma, stroke, overt status epilepticus)
 Positive pregnancy test in women aged below
50 years
 Premorbid status bedbound and uncommunicative
 Temperature <30 °C after cardiac arrest
Eligible patients were randomly assigned to hypothermia
or normothermia according to the day of the month, with
patients assigned to hypothermia on odd-numbered days.
The primary outcome measure was survival to hospital
discharge with sufficiently good neurological function to
be discharged home or to a rehabilitation facility, defined
as a cerebral performance category (CPC) of 1–2. The
CPC, shown in Table 1, is a commonly used 5-category
scale which has been the historical gold standard for
measuring neurological status after cardiac arrest [8, 9].
The 5 categories are: CPC 1, conscious and alert with
good cerebral performance; CPC 2, conscious and alert
with moderate cerebral performance; CPC 3, conscious
with severe cerebral disability; CPC 4, comatose or in per-
sistent vegetative state; and CPC 5, brain dead, circulation
preserved. Good and poor neurological outcomes were
Table 1 Cerebral performance category
CPC 1 Conscious, alert, able to work and lead a normal life. May have
minor psychological or neurological deficits (mild dysphasia,
non-incapacitating hemiparesis, or minor cranial nerve
abnormalities).
CPC 2 Conscious. Sufficient cerebral function for part-time work in
sheltered environment or independent activities of daily life
(dress, travel by public transportation, food preparation). May
have hemiplegia, seizures, ataxia, dysarthria, or permanent
memory or mental changes.
CPC 3 Conscious. Dependent on others for daily support (in an institution
or at home with exceptional family effort). Has at least limited
cognition. This category includes a wide range of cerebral
abnormalities, from patients who are ambulatory but have severe
memory disturbances or dementia precluding independent
existence, to those who are paralyzed and can communicate only
with their eyes, as in the “locked in” syndrome.
CPC 4 Unconscious. Unaware of surroundings, no cognition. No verbal
and/or psychological interaction with environment.
CPC 5 Brain dead, circulation preserved.
CPC Cerebral performance category
Table 2 Patient demographics and baseline clinical data
Variable All patients n = 21 (%) Hypothermia n = 9 (%) Normothermia n = 12 (%) P-value
Demographics
Age (years) 52.5 ± 11.0 45.9 ± 12.2 57.4 ± 7.0 0.013
Gender (male) 17 (81.0) 8 (88.9) 9 (75.0) 0.422
BSA (m2) 1.72 ± 0.18 1.71 ± 0.16 1.72 ± 0.20 0.930
Comorbidities
Hypertension 11 (52.4) 4 (44.4) 7 (58.3) 0.528
Hyperlipidaemia 10 (47.6) 6 (50.0) 4 (44.4) 0.801
Diabetes mellitus 9 (42.9) 5 (41.7) 4 (44.4) 0.899
Renal failure (CrCl <60 ml/min) 12 (57.1) 5 (55.6) 7 (58.3) 0.899
Coronary artery disease 17 (81.0) 6 (66.7) 11 (91.7) 0.149
Peripheral vascular disease 3 (14.3) 1 (11.1) 2 (16.7) 0.719
Previous stroke 1 (4.8) 0 (0) 1 (8.3) 0.375
Atrial fibrillation 1 (4.8) 0 (0) 1 (8.3) 0.375
Smoking 12 (57.1) 6 (66.7) 6 (50.0) 0.445
LVEF (%) 23.4 ± 15.8 13.9 ± 3.6 30.3 ± 17.8 0.013
Values for parametric continuous variables are expressed as mean ± standard deviation. Values for categorical variables are expressed as numbers (%)
BSA body surface area, CrCl creatinine clearance, LVEF left ventricular ejection fraction
Pang et al. Journal of Cardiothoracic Surgery  (2016) 11:43 Page 2 of 5
defined as a CPC of 1–2 and 3–5 respectively. Secondary
end points were mortality within 6 months, the length of
in-hospital stay and the rate of ECLS-related complica-
tions within seven days.
ECLS Setup & management
ECLS was instituted in all patients via percutaneous can-
nulation of the common femoral artery and vein. Stand-
ard ECLS components consisting of an extracorporeal
centrifugal pump, oxygenator and heat exchanger were
utilized. In patients randomized to receive therapeutic
induced hypothermia, cooling to a target core body
temperature of 34 °C was performed by modulating the
heat exchanger component of the ECLS circuit. The
temperature was maintained at 34 °C for 24 h in the in-
tensive care unit. Core body temperature readings were
obtained by measuring the tympanic and nasopharyngeal
temperatures as well as via sensors of the Allon 2000
(Allon, MTRE, Israel) temperature regulating console. An
intra-aortic balloon pump was inserted in all patients to
augment haemodynamic support. Intravenous heparin
was administered to prevent thrombosis within the ECLS
circuit, unless contraindicated by existing bleeding.
Statistical analysis
Statistical analyses were performed with the Statistical
Package for Social Science, version 17 (SPSS, Chicago, IL,
USA). Continuous variables were expressed as either
means with standard deviation or median with interquar-
tile range, as appropriate. These were compared using
two-tailed t-test or Mann–Whitney U-test, respectively.
Categorical variables, expressed as percentages, were ana-
lyzed with χ2 or Fisher’s exact test. All two-tailed P-values
<0.05 were taken as significant.
Findings
From Aug 2013 to Jan 2015, 21 patients (9 hypothermia, 12
normothermia) received ECLS as salvage therapy for car-
diac arrest. Patient demographics and baseline clinical data
are shown in Table 2. The mean age was 52.5 ± 11.0 years.
Seventeen patients (81.0 %) were male. Nineteen patients
(90.5 %) suffered a witnessed in-hospital cardiac arrest.
Seventeen events (81.0 %) were attributable to acute coron-
ary syndrome.
Pre-ECLS data are shown in Table 3. The initial
rhythm was pulseless ventricular tachycardia or ven-
tricular fibrillation in 7 patients (33.3 %), pulseless elec-
trical activity in 10 (47.6 %) and asystole in 4 (19.0 %).
Table 3 Pre-ECLS data
Variable All patients n = 21 (%) Hypothermia n = 9 (%) Normothermia n = 12 (%) P-value
Initial rhythm
Pulseless VT/VF 7 (33.3) 4 (44.4) 3 (25.0) 0.350
PEA 10 (47.6) 4 (44.4) 6 (50.0) 0.801
Asystole 4 (19.0) 1 (11.1) 3 (25.0) 0.422
In-hospital cardiac arrest 19 (90.5) 7 (77.8) 12 (100) 0.086
Duration of CPR (mins) 25.7 ± 15.6 29.9 ± 15.6 22.6 ± 15.5 0.300
Values for parametric continuous variables are expressed as mean ± standard deviation. Values for categorical variables are expressed as numbers (%)
CPR cardiopulmonary resuscitation, PEA pulseless electrical activity, VF ventricular fibrillation, VT ventricular tachycardia
Table 4 ECLS-related complications
Variable All patients n = 21 (%) Hypothermia n = 9 (%) Normothermia n = 12 (%) P-value
Duration of ECLS (days) 4.4 ± 2.7 4.1 ± 1.8 4.6 ± 3.2 0.675
Bleeding 5 (23.8) 2 (22.2) 3 (25.0) 0.882
Intracranial haemorrhage 1 (4.8) 0 (0) 1 (8.3) 0.375
Intrathoracic or intra-abdominal 3 (14.3) 1 (11.1) 2 (16.7) 0.719
PCT / day of ECLS (units) 2.6 ± 2.0 2.2 ± 1.7 2.9 ± 2.2 0.484
New arrhythmias 4 (19.0) 2 (22.2) 2 (16.7) 0.748
Limb ischaemia 6 (28.6) 2 (22.2) 4 (33.3) 0.577
Distal perfusion cannula 13 (61.9) 6 (66.7) 7 (58.3) 0.697
Acute renal failure 19 (90.5) 8 (88.9) 11 (91.7) 0.830
CRRT 18 (85.7) 7 (77.8) 11 (91.7) 0.368
Pneumonia 7 (33.3) 1 (11.1) 6 (50.0) 0.061
Values for parametric continuous variables are expressed as mean ± standard deviation. Values for categorical variables are expressed as numbers (%)
CRRT continuous renal replacement therapy, ECLS Extracorporeal life support, PCT packed cell transfusion
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The mean duration of CPR and ECLS were respectively,
25.7 min and 4.4 days. Target cooling to 34 °C was
achieved in all 9 patients assigned to the hypothermia
arm. ECLS-related complications are shown in Table 4.
There were no intergroup differences in the frequency of
ECLS-related adverse events.
Follow-up data are shown in Table 5. Twelve patients
(57.1 %) were successfully weaned off ECLS, of which 5
(23.8 %) survived to hospital discharge and were alive at
6 months follow-up. The causes of death in the 15
patients who died were multi-system organ failure in 12
patients (80.0 %) and severe anoxic brain injury in 3
patients (20.0 %). The median follow-up period for in-
hospital survivors was 191 (85, 399) days. Two patients
(22.2 %) in the hypothermia group, compared to 1
(8.3 %) in the normothermia group, survived with a good
neurological outcome.
Discussion
A recent large randomized trial has shown a lack of
benefit of hypothermia at a targeted temperature of
33 °C compared with a targeted temperature of 36 °C
in terms of survival and preservation of cognitive func-
tion in unconscious survivors of out-of-hospital car-
diac arrest [10, 11]. Despite these findings, therapeutic
hypothermia may still benefit patients suffering from
refractory cardiac arrest with prolonged resuscitation
unresponsive to conventional CPR, who require ECLS
as salvage therapy. ECLS-assisted CPR has been re-
ported to improve survival and neurological outcomes
compared to conventional CPR. Overall survival and
survival with good neurological function rates range
from 31 to 50 and 26 to 47 % respectively [2–4, 12].
Survival to hospital discharge and survival with good
neurological function in patients receiving therapeutic
hypothermia in our randomized cohort were 33.3 and
22.2 % respectively. Superior results have been reported
from the recent CHEER trial, during which therapeutic
hypothermia (33 °C maintained for 24 h) in conjunction
with ECLS was instituted for 24 patients, of which 13 pa-
tients (54 %) were successfully weaned from ECMO sup-
port. Survival to hospital discharge with full neurological
recovery (CPC score 1) occurred in 12 patients (50 %) [7].
The main limitation of this study is the small number
of surviving patients and total number of patients re-
cruited to date, thus limiting statistical power. Further
study recruitment may shed more light on the benefit of
therapeutic hypothermia in adult patients receiving
ECLS. In addition, patients receiving hypothermia were
significantly younger, with possibly greater potential for
neurological recovery compared to older patients.
Conclusion
The preliminary results of this randomized study suggest
that therapeutic hypothermia is safe to use in adult pa-
tients receiving ECLS, with similar complication rates
compared with ECLS without hypothermia. Further stud-
ies are warranted to measure the efficacy of this therapy.
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Table 5 Follow-up data
Variable All patients n = 21 (%) Hypothermia n = 9 (%) Normothermia n = 12 (%) P-value
Weaned from ECLS 12 (57.1) 4 (44.4) 8 (66.7) 0.309
Severe neurological dysfunction 13 (61.9) 6 (66.7) 7 (58.3) 0.697
Length of hospital stay (days) 7 (2, 22) 6 (2, 23) 7 (2, 22) 0.772
In-hospital death 15 (71.4) 6 (66.7) 9 (75.0) 0.676
Hospital discharge 5 (23.8) 3 (33.3) 2 (18.2) 0.436
Survival at 6 months 5 (23.8) 3 (33.3) 2 (18.2) 0.436
Survival (good neurological function) 3 (14.3) 2 (22.2) 1 (8.3) 0.368
Values for non-parametric continuous variables are expressed as median followed by 25th and 75th percentiles. Values for categorical variables are expressed as
numbers (%)
ECLS extracorporeal life support
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